Syncona Limited Gyroscope announces additional financing plans (6226T)
March 26 2021 - 3:06AM
UK Regulatory
TIDMSYNC
RNS Number : 6226T
Syncona Limited
26 March 2021
26 March 2021 Syncona Limited
Gyroscope Therapeutics announces additional financing plans
Syncona Ltd, a leading healthcare company focused on founding,
building and funding a portfolio of global leaders in life science,
today notes that its portfolio company, Gyroscope Therapeutics
Limited ("Gyroscope"), has announced that it expects to consider
additional capital raising options this year, which could include
an initial public offering in the United States. The timing and the
terms of any such offering have not yet been determined and are
subject to market conditions and other factors. There is no
assurance that any such additional capital raising will be
completed.
This announcement is being made pursuant to and in accordance
with Rule 135 under the U.S. Securities Act of 1933, as amended,
and does not constitute an offer to sell or the solicitation of an
offer to buy securities, and shall not constitute an offer,
solicitation or sale in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of that jurisdiction.
[ENDS]
Forward-looking statements - this announcement contains certain
forward-looking statements with respect to the portfolio of
investments of Syncona Limited. These statements and forecasts
involve risk and uncertainty because they relate to events and
depend upon circumstances that may or may not occur in the future.
There are a number of factors that could cause actual results or
developments to differ materially from those expressed or implied
by these forward-looking statements. In particular, many companies
in the Syncona Limited portfolio are conducting scientific research
and clinical trials where the outcome is inherently uncertain and
there is significant risk of negative results or adverse events
arising. In addition, many companies in the Syncona Limited
portfolio have yet to commercialise a product and their ability to
do so may be affected by operational, commercial and other
risks.
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Natalie Garland-Collins / Tim Stamper
Tel: +44 (0) 20 3727 1000
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUUNRBRAAUOURR
(END) Dow Jones Newswires
March 26, 2021 03:06 ET (07:06 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024